INIS
angiotensin
100%
insulin
62%
diabetes mellitus
62%
rats
50%
glucose
37%
diseases
25%
doses
25%
uptake
25%
levels
12%
animals
12%
drugs
12%
in vitro
12%
therapy
12%
sensitivity
12%
stimulation
12%
plasma
12%
hyperglycemia
12%
blood
12%
increasing
12%
metabolic diseases
12%
oral administration
12%
oligosaccharides
12%
elevation
12%
chronic administration
12%
renin
12%
Medicine and Dentistry
angiotensin[1-7]
87%
Maturity Onset Diabetes of the Young
75%
Diseases
25%
Combination Therapy
25%
Insulin Signaling
25%
Glucose Uptake
25%
Therapeutic Procedure
25%
Oral Drug Administration
12%
Glucopyranosyl Lipid A
12%
In Vitro
12%
Glucose
12%
Insulin Sensitivity
12%
Water-Electrolyte Imbalance
12%
Cardiomyocyte
12%
Insulin Resistance
12%
Hyperglycemia
12%
Renin Angiotensin Aldosterone System
12%
Chronic Drug Administration
12%
Therapy Effect
12%
Diabetic Nephropathy
12%
Cyclodextrin
12%
Antidiabetic Agent
12%
Pharmacological Stimulation
12%
Plasma
12%
Blood
12%
Pharmacology, Toxicology and Pharmaceutical Science
angiotensin[1-7]
87%
Non Insulin Dependent Diabetes Mellitus
75%
Diseases
25%
Rat Model
25%
Rat
25%
Glucopyranosyl Lipid A
12%
Insulin
12%
Insulin Resistance
12%
Glucose
12%
Diabetes Mellitus
12%
Metabolic Disorder
12%
Cyclodextrin
12%
Diabetic Nephropathy
12%
Antidiabetic Agent
12%
Hyperglycemia
12%
Transgenic Rat
12%
Neuroscience
angiotensin[1-7]
87%
Diabetes Mellitus
62%
Insulin Signaling
25%
Diabetes
25%
Glucose Transport
25%
In Vitro
12%
Hyperglycemia
12%
Cyclodextrin
12%
Glucopyranosyl Lipid A
12%
Biochemistry, Genetics and Molecular Biology
Rat Model
25%
Glucose Transport
25%
Insulin Signaling
25%
Rat
25%
Dose
25%
Insulin Resistance
12%
Renin Angiotensin Aldosterone System
12%
Cyclodextrin
12%
Insulin Sensitivity
12%
Transgenic Rat
12%
Hyperglycemia
12%
Glucose Blood Level
12%
Insulin Blood Level
12%
Pharmacological Stimulation
12%
Animal Models
12%